# A Single Dose Bioequivalence Study of WD-1602 Versus Pradaxa® in Healthy Subjects Under Fed Condition

> **NCT04592822** · PHASE1 · UNKNOWN · sponsor: **Hong Kong WD Pharmaceutical Co., Limited** · enrollment: 20 (estimated)

## Conditions studied

- Anticoagulant

## Interventions

- **DRUG:** WD-1602
- **DRUG:** Pradaxa®

## Key facts

- **NCT ID:** NCT04592822
- **Lead sponsor:** Hong Kong WD Pharmaceutical Co., Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-01-06
- **Primary completion:** 2021-06-06
- **Final completion:** 2021-12-06
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2020-11-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04592822

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04592822, "A Single Dose Bioequivalence Study of WD-1602 Versus Pradaxa® in Healthy Subjects Under Fed Condition". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04592822. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*